The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.
Budesonide (Pulmicort®) CFC-free has been accepted for use in the treatment of asthma based upon it replacing the equivalent CFC-containing metered dose inhalation device.
Brinzolomide eye drops (Azopt®) have been accepted for the treatment of elevated intraocular pressure in ocular hypertension and open-angle glaucoma.
Fluticasone furoate (Avamys®) nasal spray has been accepted for the treatment of the symptoms of allergic rhinitis in adults, adolescents (12 years and over) and children (6 to 11 years). The appraisal notes that other intranasal steroids are available at a lower cost.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.